Literature DB >> 22161810

Impact of recovery on fraction unbound using equilibrium dialysis.

Li Di1, John P Umland, Patrick E Trapa, Tristan S Maurer.   

Abstract

Historically, recovery had been used to evaluate the data quality of plasma protein binding or tissue binding obtained from equilibrium dialysis assays. Low recovery was often indicative of high nonspecific binding, instability, or low solubility. This study showed that, when equilibrium was fully established in the dialysis assay, low recovery due to nonspecific binding had no impact on the determination of fraction unbound. The conclusion was supported by the principles of the equilibrium dialysis assay, experimental data, and mathematic simulations. The results suggested that the use of recovery as an acceptance criterion for the equilibrium dialysis assay in drug discovery was too restrictive, and introduced the additional burden of repeating studies unnecessarily.
Copyright © 2011 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2011        PMID: 22161810     DOI: 10.1002/jps.23013

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  14 in total

1.  Interpreting physicochemical experimental data sets.

Authors:  Nicola Colclough; Mark C Wenlock
Journal:  J Comput Aided Mol Des       Date:  2015-06-09       Impact factor: 3.686

Review 2.  Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities.

Authors:  Donglu Zhang; Cornelis E C A Hop; Gabriela Patilea-Vrana; Gautham Gampa; Herana Kamal Seneviratne; Jashvant D Unadkat; Jane R Kenny; Karthik Nagapudi; Li Di; Lian Zhou; Mark Zak; Matthew R Wright; Namandjé N Bumpus; Richard Zang; Xingrong Liu; Yurong Lai; S Cyrus Khojasteh
Journal:  Drug Metab Dispos       Date:  2019-07-02       Impact factor: 3.922

3.  Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Authors:  Nigel J Waters; R Scott Obach; Li Di
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Why 90% of clinical drug development fails and how to improve it?

Authors:  Duxin Sun; Wei Gao; Hongxiang Hu; Simon Zhou
Journal:  Acta Pharm Sin B       Date:  2022-02-11       Impact factor: 14.903

5.  An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Hsin-Pin Ho Liang; Danielle Weiner; Jacqueline Gonzales; Laura E Via; Véronique Dartois
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

6.  Prediction of Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Fabio Zuccotto; Ho Hsinpin; Lars Sandberg; Laura E Via; Gwendolyn A Marriner; Thierry Masquelin; Paul Wyatt; Peter Ray; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2016-07-06       Impact factor: 5.084

7.  Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.

Authors:  Matthew Zimmerman; Jodi Lestner; Brendan Prideaux; Paul O'Brien; Isabela Dias-Freedman; Chao Chen; Jillian Dietzold; Isaac Daudelin; Firat Kaya; Landry Blanc; Pei-Yu Chen; Steven Park; Padmini Salgame; Jansy Sarathy; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor.

Authors:  David L Gray; John A Allen; Scot Mente; Rebecca E O'Connor; George J DeMarco; Ivan Efremov; Patrick Tierney; Dmitri Volfson; Jennifer Davoren; Edward Guilmette; Michelle Salafia; Rouba Kozak; Michael D Ehlers
Journal:  Nat Commun       Date:  2018-02-14       Impact factor: 14.919

9.  Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.

Authors:  Rong Chen; Mingzhao Zhu; Rajan R Chaudhari; Omar Robles; Yuling Chen; Wesley Skillern; Qun Qin; William G Wierda; Shuxing Zhang; Kenneth G Hull; Daniel Romo; William Plunkett
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

10.  Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing.

Authors:  Meera E Modi; Mark J Majchrzak; Kari R Fonseca; Angela Doran; Sarah Osgood; Michelle Vanase-Frawley; Eric Feyfant; Heather McInnes; Ramin Darvari; Derek L Buhl; Natasha M Kablaoui
Journal:  J Pharmacol Exp Ther       Date:  2016-05-23       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.